Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE versus FUROXONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE versus FUROXONE.
ATOVAQUONE vs FUROXONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain complex III (cytochrome bc1 complex) in parasites, thereby disrupting pyrimidine synthesis and energy metabolism.
Furazolidone is a nitrofuran antimicrobial that inhibits bacterial monoamine oxidase and disrupts bacterial DNA synthesis by undergoing reduction by bacterial nitroreductases to reactive intermediates that cause DNA cross-linking and damage.
750 mg oral suspension twice daily for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia; 1500 mg oral suspension once daily for prophylaxis.
100 mg orally four times daily
None Documented
None Documented
Clinical Note
moderateAtovaquone + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Atovaquone."
Clinical Note
moderateAtovaquone + Artemether
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether."
Clinical Note
moderateAtovaquone + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine."
Clinical Note
moderateAtovaquone + Dapsone
Terminal elimination half-life is approximately 2-3 days (67 hours) in adults, prolonged in renal or hepatic impairment.
Terminal elimination half-life is approximately 1.5–2 hours; clinically, this supports dosing every 6 hours for sustained antibacterial effect.
Primarily fecal (>94%) as unchanged drug; renal excretion is minimal (<1%).
Primarily renal (approximately 65%) as unchanged drug; biliary/fecal excretion accounts for about 35%.
Category A/B
Category C
Antiprotozoal
Antibacterial/Antiprotozoal
"The risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone."